Brought to you by 
Bristol-Myers swaps with Lipha for US Glucophage rights
22 Mar 2013
Executive Summary
Bristol-Myers Squibb gains US marketing rights to Glucophage, a prescription drug for treating diabetes, in a swap with Merck KGAA's Lipha SA for marketing rights in France to certain BMS products.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Marketing
- Co-Promotion
- Marketing (Licensing)
- Product or Technology Swap
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bristol-Myers swaps with Lipha for US Glucophage rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice